Glaxosmithkline Pharmaceuticals Ltd vs Innova Captab Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2345 as of 04 May 11:00 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 yearsThe P/E Ratio of Innova Captab Ltd changed from 27.2 on March 2024 to 39.2 on March 2025 . This represents a CAGR of 20.05% over 2 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Innova Captab Ltd changed from ₹ 2564 crore on March 2024 to ₹ 5021 crore on March 2025 . This represents a CAGR of 39.93% over 2 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The revenue of Innova Captab Ltd for the Dec '25 is ₹ 451.95 crore as compare to the Sep '25 revenue of ₹ 384.57 crore. This represent the growth of 17.52% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The ebitda of Innova Captab Ltd for the Dec '25 is ₹ 71.05 crore as compare to the Sep '25 ebitda of ₹ 56.05 crore. This represent the growth of 26.76% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The net profit of Innova Captab Ltd changed from ₹ 29.48 crore to ₹ 42.15 crore over 7 quarters. This represents a CAGR of 22.67% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 yearsThe Dividend Payout of Innova Captab Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Innova Captab Ltd

Innova Captab Limited was incorporated as Harun Health Care Private Limited', dated January 3, 2005, as a Private Limited Company at Mumbai.
Thereafter, the name of the Company was changed from Harun Health Care Private Limited' to Innova Captab Private Limited', and a fresh Certificate of Incorporation dated February 2, 2010, was issued by RoC to the Company.
Subsequently, Company got converted to a Public Company on July 12, 2018, and the name was changed to Innova Captab Limited', dated July 26, 2018. The Company is an integrated pharmaceutical company in India with a presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports.
Their business includes contract development and manufacturing organization (CDMO) business providing manufacturing services to Indian pharmaceutical companies, domestic branded generics business and an international branded generics business.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Innova Captab Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Innova Captab Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 39,566 Cr while Market cap of Innova Captab Ltd is 4,298 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Innova Captab Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Innova Captab Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Innova Captab Ltd?

As of May 4, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2335.6. On the other hand, Innova Captab Ltd stock price is INR ₹751.1.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Innova Captab Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Innova Captab Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.